Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINBO-p53abn RED olaparib maintenance in p53-abnormal endometrial cancer
2023-503886-44-00Phase 3Authorised
- Sponsor
- Gustave Roussy
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in endometrial cancer (EC) comparing Maintenance olaparib with Observation (2 arms). Primary endpoint: Recurrence-free survival. Planned start Jun 2024; status: authorised.
02
Drugs
olaparib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2023-503886-44-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503886-44-00.